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Antibody-mediated rejection (AMR) of solid organ
transplants (SOT) is characterized by damage triggered
by donor-specific antibodies (DSA) binding donor Class
I and II HLA (HLA-I and HLA-II) expressed on endothelial
cells. While F(ab0)2 portions of DSA cause cellular
activation and proliferation, Fc regions activate the
classical complement cascade, resulting in comple-
ment deposition and leukocyte recruitment, both
hallmark features of AMR. We characterized the ability
of an anti-C1s monoclonal antibody, TNT003, to inhibit
HLA antibody (HLA-Ab)-induced complement activa-
tion. Complement deposition induced by HLA-Ab was
evaluated using novel cell- and bead-based assays.
Human aortic endothelial cells (HAEC) were cultured
with HLA-Ab and human complement; production of
activated complement proteins was measured by flow
cytometry. Additionally, C3d depositionwasmeasured
on single antigen beads (SAB) mixed with HLA-Ab
and human complement. TNT003 inhibited HLA-Ab
mediated complement deposition on HAEC in a
concentration-dependent manner; C3a, C4a and C5a
anaphylatoxin production was also diminished by
TNT003. Finally, TNT003 blocked C3d deposition
induced by Class I (HLAI-Ab)- and Class II (HLAII-Ab)-
specific antibodies on SAB. These data suggest TNT003
may be useful for modulating the effects of DSA, as
TNT003 inhibits complement deposition and split
product formation generated by HLA-I/II-Ab in vitro.
Abbreviations: AMR, antibody-mediated rejection; CBA,
cytometric bead array; CDC, complement-dependent
cytotoxicity; cPRA, calculated panel reactive antibody;
DSA, donor-specific antibodies; EBV, Epstein–Barr virus;
EC, endothelial cell; EPC, endothelial progenitor cell;
FcgR, Fc gamma receptor; HAEC, human aortic endothe-
lial cells; HLA-I, Class I human leukocyte antigen; HLA-II,
Class II human leukocyte antigen; HLA-Ab, human
leukocyte antigen antibody; HLAI-Ab, antibody specific
for Class I human leukocyte antigen; HLAII-Ab, antibody
specific for Class II human leukocyte antigen; HUVEC,
human umbilical vein endothelial cell; IFNg, interferon
gamma; IVIG, intravenous immunoglobulin; mAb,
monoclonal antibody; MAC, membrane attack complex;
MFI, median fluorescence intensity; SAB, single antigen
beads; TNFa, tumor necrosis factor alpha
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Introduction
The classical pathway of complement activation is induced
by C1 complex recognition of antibody-opsonized antigen.
Upon binding Fc, C1q undergoes a conformational change,
activating the associated C1r/C1s proteases. Active C1s is
responsible for cleavage of downstream complement
proteins, which form the convertases essential for comple-
ment pathway propagation and amplification. Additionally,
upon enzymatic cleavage of zymogens, soluble split
products known as anaphylatoxins are released, which
stimulate local cells and recruit leukocytes to inflammatory
sites. Lastly, terminal membrane attack complex (MAC) is
formed by complement protein polymerization, inducing
pores in the cell membrane, resulting in osmotic lysis of the
target (1,2). Increased activation of the classical complement
cascade is readily apparent in antibody-mediated rejection
(AMR) (cardiac, renal, and pancreatic), as the presence of
circulating immunoglobulin (Ig) and intragraft complement
deposition are important markers for diagnosing AMR (3–7).
While immunosuppressive regimens help to dampen
adaptive alloimmune responses against polymorphic HLA
proteins, roughly 20% of transplant patients still develop
posttransplant donor-specific antibodies (DSA), which sig-
nificantly impact graft loss, suggesting a need for additional
therapeutics (8–15). DSA binding to HLA on endothelial cells
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(EC) elicits a three-pronged response: first, EC become
activated, proliferate, migrate and express adhesion mole-
cules (16–19); second, the Fc of DSA serve as handles for
activated leukocytes to bind, enhancing leukocyte–endothe-
lial interactions and amplifying the process of extravasation
into the graft (20,21); lastly, the Fc region plays an additional
role in activating complement via the classical pathway,
resulting in the production of anaphylatoxins as well as split
product deposition on the EC surface. Complement activa-
tion may potentiate leukocyte infiltration in addition to
causing complement-mediated injury to the graft (22,23).
Recently, eculizumab, a humanized monoclonal antibody
(mAb) against complement protein C5, has been used to
ameliorate the effects of DSA-mediated complement
activation in both cardiac and renal AMR (24–29). By
blocking C5 activation, MAC formation and complement-
mediated injury are reduced (30). This intervention may
diminish terminal complement damage to the graft, and
current clinical trials (NCT01327573, NCT02013037 and
NCT01399593) are underway to determine the efficacy of
eculizumab in preventing allograft rejection. Alternatively,
others have suggested thatMAC formation rarely occurs on
endothelium, as EC express high amounts of complement
inhibitory receptors (31,32). Therefore, the early events in
complement activation, such as anaphylatoxin release and
complement split product deposition on the endothelium
(resulting in EC activation and leukocyte recruitment to the
graft), would still occur despite C5 blockade (22,23,33). In
this regard, others have reported that C5 inhibition is an
ineffective therapy for prevention of AMR (34–36),
highlighting the need for additional therapies to minimize
early DSA effects. In this study, we elucidate the ability of
TNT003, a mAb against active C1s, and a specific and
potent inhibitor of complement, to block HLA antibody
(HLA-Ab) induced complement activation in vitro. In both
cell- and bead-based assays, TNT003 inhibits complement
activation by HLA-Ab, as determined by its ability to prevent
both complement deposition and anaphylatoxin formation.
By targeting C1s, TNT003 blocks the initiation of the
classical pathway, resulting in little anaphylatoxin formation
and/or split product deposition, thereby inhibiting early
complement-mediated effects elicited by DSA.
Materials and Methods
Ethics statement
Informedwritten consent for use of the aortic tissue as an anatomical gift for
research was obtained by OneLegacy (a federally designated organ
procurement organization) at the time of organ donation from the next of
kin or authorized party. The use of the human aortic tissue for the research
described hereinwas approved by theOneLegacy Biomedical ReviewBoard
under the agreement #RS-02-10-2 and UCLA MTA2009-561.
Reagents
Monoclonal mouse anti-human C1s, or TNT003, was made as previously
described (37). TNT003, nonspecific isotype control antibody (Control,
IgG2a, #BE0085; BioXCell, West Lebanon, NH), anti-C5 (#A217; Quidel, San
Diego CA), and a nonspecific isotype control antibody (Control, IgG1,
#BE0083; BioXCell) were cleaved to produce F(ab0)2 fragments (F(ab0)2 Prep
Kit, #44988; Thermo Scientific, Rockford, IL), thereby removing any
nonspecific Fc-mediated effects of the inhibitor. Control F(ab0)2 antibodies
were used in assays at the same concentration as the highest dose of
TNT003. Single donor normal human serum (NHS) was used as source of
active complement (#IPLA-CSERS; Innovative Research, Novi, MI).
Monoclonal and polyclonal antibody sources
HLA-Ab came from two main sources. First, human monoclonal antibodies
(mAb), previously described and characterized (38,39), with varying HLA
specificities (A2, A2/28 and A3/11) were used at different concentrations.
Second, UCLA HLA reference sera and broadly reactive >80% PRA pooled
positive serum (PS), previously characterized by single antigen assays
(unpublished data, see ([40])), were chosen for specificities matching the
HLA type of cells used in subsequent experiments (see Tables S1–S3).
Human sera samples were heat inactivated at 568C for 30min, followed by
centrifugation at 9800g for 5min to clear protein aggregates.
Cells and culture conditions
Primary human aortic endothelial cells (HAEC) were isolated from the aortic
rings of deceased donors in accordancewithUCLA Institutional ReviewBoard
protocol (IRB00-01-023) and cultured as previously described (41,42). All
experimentswere performed usingHAEC fromat least three different donors
and between passages 4–8. For experiments requiring Class II human
leukocyte antigen (HLA-II) expression, HAEC were stimulated with tumor
necrosis factor alpha (TNF-a) (200U/mL) and interferongamma (IFN-g) (500U/
mL) for 48h to upregulate HLA-II molecules on the cell surface (Figure S1).
Epstein-Barr virus (EBV)-transformed human B cells expressing high levels of
HLA-II (Figure S1) were cultured in RPMI-1640 with 10% fetal calf serum
(FCS), 50U/mL antibiotics. All cells used in these studies were HLA-A, -B, -C,
-DR, -DQ typed at the UCLA Immunogenetics Center (UIC) by SSO and/or
SSP technologies (One Lambda, Canoga Park, CA) (see Table S1).
Flow cytometry
C4dwas detectedwith amousemAb specific for a neoepitope only revealed
upon C4b cleavage to C4c/d (#A215; Quidel). Goat anti-mouse IgG Fc-Alexa
Fluor 647 (AF647, #405322; BioLegend, San Diego, CA) was used to detect
C4d mAb binding. Goat anti-human IgG F(ab0)2-fluorescein isothyocyanate
(FITC) was used to detect human IgG bound to the surface of cells (#109-
096-170; Jackson ImmunoResearch, West Grove, PA). Mouse anti-HLA-I
W6/32 (hybridoma HB-95; ATCC, Manassas, VA) was conjugated to Pacific
Blue (PB, #P30013; LifeTech, San Diego, CA). CD46-phycoerythrin (PE)
(#352401), CD55-PE-Cy7 (#311314), CD59-FITC (#304706) and HLA-DR/
DQ/DP-AF647 (#361703) were from BioLegend. All cells were stained in
staining buffer (PBS with 2% FCS), acquired by LSRFortessa (BD, San
Diego, CA), and analyzed using FlowJo Software (TreeStar, Ashland, OR).
Cell-based complement assays
EBV B cells or HAEC (5 104cells/well, 96-well plate) were incubated with
HLA-Ab (30min, 48C). Serum from sensitized individuals, as a source of HLA-
Ab,was incubatedwith cells in a 1mL:1000 cells ratio, aspreviously determined
by EC cross-match assays. Unbound antibody was washed away, and NHS
(source of complement, final concentration 25%) containing inhibitor (TNT003
or anti-C5) or control antibody (nonspecific IgG2a or IgG1, respectively) was
added to cells (30min room temperature [RT]). Cells were pelleted,
supernatants were saved for analysis of anaphylatoxin production, and cells
were washed in staining buffer twice, followed by the addition of conjugated
antibody cocktails for 30min on ice. Cells were then washed, resuspended in
staining buffer, and acquired by flow cytometry as above. Supernatants were
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analyzed for C3a,C4a, andC5a using the humananaphylatoxin cytometric bead
array (CBA) kit (#561418; BD) per manufacturer’s protocol.
Complement detection: Bead-based assays
The C3d bead-based Luminex assay to detect complement activation
induced by HLA-Ab was performed according to manufacturer’s protocol
(Immucor, Stamford, CT). Briefly, heat inactivated human sera were
incubated with Lifecodes LSA Class I and II single antigen beads (SAB) in
Whatman 96-well filter plates (30min, RT, shaking 220 rpm). NHS (final
concentration of 37.5%) was added as a source of complement to the
samples, and incubated for 30min (RT, shaking). Plates were washed five
times with the provided wash buffer, and stained with anti-C3d-PE (30min,
RT, shaking, 200 rpm). Plates were washed twice, followed by sample
resuspension in wash buffer, and acquisition using Luminex technology
(Luminex100, Luminex, Austin, TX). Clinically validated sera (negative serum
[NS] without HLA-Ab; pooled PS, with greater than 80% calculated panel
reactive antibody [cPRA]) were used as controls for complement activation
(Figure S2). To determine TNT003 ability to block C3d deposition, various
amounts of TNT003 or control mAbwere titrated into NHS before addition to
the C3d reaction. C1q binding to HLA-Ab was measured using the C1q
Screen assay (One Lambda). Briefly, patient sera were incubated with C1q
and SAB in the presence of TNT003, and C1q binding was detected using a
C1q-PE antibody, and acquired by Luminex.
Cardiac transplant patient sera
UCLA has a large, well characterized, cardiac transplant patient cohort. This
IRB-approved study (IRB#01-08-015-21) comprised a retrospective cohort
design of over 200 consented cardiac allograft recipients, from the period of
01/2009–12/2013. From this group, we selected adult patient samples (18
years old), which contained donor specific antibodies (DSA MFI> 1000,
n¼ 51 of 145 adult samples). Of these 51 samples, 36 had date-matched
allograft biopsies, 10 of which scored positive for AMR (Table S4). These 10
individual patient sera samples were analyzed for their capacity to induce
complement activation using the high-throughput bead-based C3d assay
(Immucor, (43)). Diagnosis of AMR was based on the histological and
immunohistochemical criteria independent of serology, consistent with the
2013 ISHLTWorking Formulation (pAMR) (5). Diagnostic criteria for ACR are
previously outlined (44,45).
Statistical analyses
The significance of TNT003 inhibition, as compared to control, was
determined using a paired Student’s t-test. Data are represented as
meanSEM. Linear regression analysis was performed to determine
significance of concentration-dependent inhibition of complement activation
by TNT003. The threshold for statistical significance was p 0.05, and, due
to the study’s novel nature aswell as small number of subjects, no correction
for multiple comparisons was made. In plots, the following symbols are
used: ns¼ not significant (p> 0.05);  for p< 0.05;  for p< 0.01;  for
p< 0.001 and  for p< 0.0001. Statistical analyses were performed using
STATA Software (Release 13; StataCorp, College Station, TX) and Graphpad
Software (V6; Prism, La Jolla, CA).
Results
TNT003 inhibits HLA-Ab induced complement
activation on endothelial cells
Few groups have demonstrated in vitro detection of
complement activation by HLA-Ab binding to the surface
of EC (46,47). To determine if HLA-Ab bound to HAECwere
capable of fixing complement, we incubated HLA-A2þ
HAEC (EC3, 4 or 6, see Table S1) with HLA-A2 mAb in the
presence of NHS as a source of complement. The levels of
human IgG bound to the surface of the cells increased
proportionally to the amount of mAb added (Figure 1A).
Additionally, the level of antibody bound correlated with the
amount of activated complement, as detected by C4d
staining on the surface of the cell (Figure 1B). TNT003 was
added in a concentration-dependent manner to establish
the effective concentration for use in further cell-based
assays. Increased quantities of TNT003 did not alter HLA-
Ab binding to the surface of HAEC (Figure 1C), but caused a
decrease in C4d deposition (Figure 1D). We noted a sharp
slope in effectiveness of TNT003 between 5 and 10mg/mL,
most likely due to inhibitor saturation of complement C1s in
the system. Of note, experiments performed with incuba-
tion of TNT003 with HAECþHLA-Ab, prior to addition of
NHS, did not significantly impair TNT003 blockade of C4d
deposition (data not shown) suggesting no temporal
restrictions on TNT003 function.
Given that high levels of a human HLA-A2 mAb were
capable of inducing complement activation, it was of
Figure 1: TNT003 inhibits monoclonal HLA–Ab induced
complement deposition. Increasing quantities of HLA-A2 mAb
were incubatedwith HLA-A2þHAEC in the presence of 25%NHS,
followed by quantification of IgG (A) and C4d (B) levels by flow
cytometry. Additionally, TNT003 or control was added to NHS
before addition to HAECþHLA-A2mAb, followed by quantification
of IgG (C) and C4d (D) levels. HLA-A2mAbwas added in increasing
concentrations (circles—5mg/mL; triangles—2.5mg/mL; squares—
1.25mg/mL; diamonds—0.625mg/mL), and control antibody (‘‘C’’)
was used at the same dose of the highest quantity of TNT003
(20mg/mL). Data are presented as median fluorescence intensity
(MFI) of IgGorC4dstaining on the cell surface froma representative
of three separate experiments.
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interest to see whether HLA-Ab against HLA-I (HLAI-Ab) or
HLA-II (HLAII-Ab) present in sensitized human sera at
physiological levels were able to activate complement in a
similar manner. We incubated HAEC with sera containing
HLA-Ab of matching specificities (see Table S1). Sera
containing specific HLAI-Ab bound resting EC in a HLA-I-
restricted manner, and the amount of IgG bound correlated
with increased C4d deposition on the cell surface
(Figure 2A). Despite increased binding of IgG compared
to negative serum without HLA-Ab (NS), some sera were
incapable of inducing C4d deposition (S1, see Figure 2A). In
order to evaluate HLAII-Ab-dependent complement activa-
tion, we stimulated HAEC with TNF-a and IFN-g to
upregulate HLA-II, as resting HAEC do not express HLA-II
(Figure S1, ([48–51])). Again, sera with greater levels of
HLAII-Ab resulted in higher levels of IgG bound to HAEC,
and exhibited increased quantities of C4d deposition
(Figure 2B). Of the sera which bound HAEC and induced
complement over that of NS, we analyzed the ability of
TNT003 to block this complement activation. TNT003 did
not interfere with HLA-Ab recognition of HLA-I, but
inhibited complement deposition induced by various sera
on different primary HAEC (Figures 2C and D). Additionally,
TNT003 did not alter HLA-Ab recognition of HLA-II, and
again significantly inhibited HLAII-Ab induced complement
deposition to below background levels (Figures 2E and F).
To demonstrate that this activity was specific to HLA and
complement as well as translatable to all cell types, we
tested TNT003 inhibition of the classical complement
pathway using HLA-typed EBV-transformed human B cells
as a source of HLA antigen.Of note, TNT003was capable of
inhibiting both HLAI-Ab- and HLAII-Ab-mediated comple-
ment activation on the surface of B cells (Figure S3).
Inhibiting activation of the classical pathway at the level of
C1s should result in decreased complement deposition
on the cell surface, as well as minimize production of
anaphylatoxins. Importantly, these anaphylatoxins are noted
chemoattractants, and have been shown both in vitro and
in vivo to exacerbate rejection through leukocyte recruitment
and modulation (2,52–55). We demonstrated that, upon
complement activation byHLA-Abbound toHAEC, the levels
of C4a, C3a and C5a were decreased in the presence of
TNT003 (Figures 3A–C), though not significantly. However,
Figure 2: Complement activation by HLAI-Ab and HLAII-Ab is blocked by TNT003. Quantification of IgG binding (solid bars) and C4d
deposition (hashed bars) on resting (A) or TNF-a/IFN-g-stimulated (B) HAEC induced by UCLA HLA reference sera containing HLA-Ab with
HLA-I (A) or HLA-II (B) specificities (see Tables S1–S3). Data are presented asMFI of IgG andC4d, and are a representation of three separate
experiments. Strengths of HLA-Ab (SABMFI) against relevant HLA-I/II alleles are indicated below each serum. IgG and C4dweremeasured
when resting (C, D) or TNF-a/IFN-g-stimulated (E, F). HAEC with disparate alleles were incubated with different UCLA HLA reference sera.
Each point indicates a unique pairing of HLA-I/II expressing HAEC with a serum of matching HLA-Ab specificity. TNT003 and control were
added at a concentration of 10mg/mL.
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as complement deposition on EC is not as robust as on
B cells, possibly due to increased levels of complement
inhibitory proteins CD46 and CD55 (Figure S1), we added
a pooled positive sera (PS) containing HLA-Ab to B cells in
the presence of complement, and measured anaphylatoxin
levels. Production of all three anaphylatoxins was inhibited
in the presenceofTNT003 (Figures3D–F). Collectively, these
data suggest that when complement activation is robust,
blockade of C1s activation would be valuable in ameliorating
early DSA-induced complement-mediated effects. Detailed
analysis of one reaction with strong complement induction
on the surface of HAEC shows that TNT003 inhibits
progressive activation of the complement cascade, as C4d
deposition and anaphylatoxin formation are all abrogated
with the addition of TNT003 (Figure 4).
In vitro diagnostic assessment of TNT003
Currently, Luminex-based technology is used to detect
HLA-Ab in patient sera. New assays are available for
prediction of complement binding and/or activating DSA,
such as the C1qScreen assay from One Lambda (56–59),
and more recently a C3d deposition assay from Immu-
cor (43), which detects physiological activation of human
complement. C3d deposited on the surface of the beads is
detected by a PE-conjugated C3d mAb and acquired using
Luminex. Thus,we used the C3d assay as anothermeasure
of complement induction by HLA-Ab. Three UCLA HLA
reference serawith broadHLA-I specificities (single antigen
MFI> 1000 was scored positive; see Table S2), contained
complement fixing antibodies indicated by increased C3d
deposition over NS (Figure 5A). Each serum contained a
Figure 3: TNT003decreases early anaphylatoxin formation.Supernatants fromcomplement deposition experimentswere analyzed for
split product formation using CBA technology, a flow-based bead array specific for human anaphylatoxin quantification. C4a (A), C3a (B), and
C5a (C) productionweremeasured from reactions of PS (>80%PRApooled positive serum) binding toHAEC, and addition of complement in
the presence of control or TNT003 (10mg/mL). Additionally, the same assay was performed with EBV-transformed B cells as the source of
HLA-I/II, and anaphylatoxin formation was assayed (D–F).
Figure 4: TNT003 inhibition of HLA-Ab-mediated complement
activation results in decreased levels of early split products.
Examination of HLA-Ab binding (IgG) and complement induction
(C4d, C4a, C3a, andC5a), by PS (>80%PRApooled positive serum)
on EC7, in the presence of control or TNT003. Fold change was
calculated by dividing the variable value (control or TNT003) by the
control value. The dashed line at y¼1 is indicative of baseline
values as per normalization to control.
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different number of allele-specific HLA-Ab capable of
inducing C3d, as expected due to their varying specific-
ities (determined by SAB testing, see Table S2). To
determine the concentration of TNT003 required for
complement inhibition, we titrated TNT003 into C3d
reactions using pooled HLA-I-specific sera (S10, S11, and
S12) as a source of HLA-Ab induction of C3d. Deposition
by pooled HLA-I-specific sera was significantly inhibited
by TNT003 in a concentration-dependent manner
(R2¼0.55, p<0.0001, Figure 5B). Additionally, we
performed the assay using three HLA-II-specific sera
(see Table S3), and showed similar induction of C3d
deposition (Figure 5C). Complement activation by pooled
HLA-II-specific sera (S7, S13, and S14) was also
significantly decreased in the presence of TNT003
(R2¼ 0.63, p< 0.0001, Figure 5D). Notably, the required
concentration of TNT003 for inhibition of HLA-Ab-induced
complement activation was greater in bead-based assays
(25mg/mL) than cell-based assays (10mg/mL). This is
most likely due to the increased quantity of available C1s
in the bead assay, as well as greater antigen density and
lack of complement inhibitory receptors on the surface of
beads compared to cells, all requiring larger quantities of
TNT003 to block complement activation.
Figure 5: HLA-Ab induction of C3d is inhibited by TNT003 in a novel Luminex-based assay. (A) Three UCLAHLA reference sera (S10,
S11, and S12; see Table S2) containingHLA-Ab specific for HLA-I were analyzed for C3d deposition on beads expressingHLA-I recombinant
antigens. Bead analysiswas subset into either those negative for single antigen (SAB, closed circles), or positive for single antigen (SABþ,
open circles,MFI>1000). Fold C3d induced by each allelewas determined by dividing the beadMFI of the serumsample by the beadMFI of
the NS sample, to account for background complement activation on each individual bead, i.e. MFI(sample)/MFI(NS)¼Fold C3d. (B) S10, S11,
and S12were combined in equal volumes to create a pooledHLA-I specific serum, and TNT003was added to the C3d reaction; control (‘‘C’’)
antibodywas added in the same amount as the highest TNT003 concentration. Beads positive for C3d in the presenceof control (fold change
C3d2, n¼30) were analyzed for inhibition of C3d in response to a TNT003 concentration curve. (C) In addition, three sera with HLA-Ab
against HLA-II (S7, S13, and S14; see Table S3) were analyzed for C3d deposition on SAB expressing HLA-II antigens. (D) For TNT003
inhibition of HLAII-Ab, combination of S7, S13, and S14 made a pooled HLA-II specific serum which was tested for C3d deposition in the
presence of TNT003; beads with a fold change C3d2 (n¼16) were evaluated for TNT003 inhibition. Dashed line at y¼1 is indicative
of baseline C3d deposition.
Thomas et al
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TNT003 inhibits complement induced by
AMR-associated DSA
We next sought to determine whether AMR-associated
DSA from cardiac transplant recipients could induce
complement activation on the C3d platform, and whether
this deposition was blocked by TNT003. We found 10
patients in the UCLA cardiac cohort who had biopsy-proven
AMR and a date-matched serum sample positive for DSA
(Table S4). Of these 10 patients, 3 had HLAI-Ab that
activated complement, and all had HLAII-Ab that were
capable of inducing complement activation, as measured
by C3d deposition. In addition, TNT003 substantially
abrogated complement deposition induced by AMR-
associated DSA from these 10 cardiac transplant patients
(Figures 6A and B). Moreover, TNT003 blockade of
complement activation was equally efficient at blocking
complement deposition by both HLAI-Ab and HLAII-Ab
(Figure 6C).
TNT003 blocks complement activation upstream of
other complement inhibitors
C4d deposits on the endothelium of graft tissue are a noted
histological marker of HLA-Ab-induced complement activa-
tion during AMR (5). Current therapies targeted at
minimizing complement-mediated damage to the graft
aim to block complement protein activation (27), specifically
monoclonals directed against C5, which inhibit C5a
production and MAC formation (30). It was of interest to
compare the ability of TNT003 and an anti-C5 antibody to
block early complement activation. As HLA-Ab-mediated
complement activation is more robust when using B cells
as a source of HLA antigen, we analyzed PS-induced cell
surface deposition and anaphylatoxin production on EBV-
transformed B cells in the presence of both complement
inhibiting mAbs. Neither inhibitor interfered with antibody
recognition of HLA-I/II (Figure 7A). TNT003 prevented C4d
deposition (Figure 7B), as well as C4a and C3a production
(Figures 7C and D) more effectively than a murine
neutralizing mAb to C5 (anti-C5). However, there was no
difference between TNT003 and anti-C5 with respect to
decreased C5a production (Figure 7E). Similar results were
obtained using HAEC as sources of HLA-I/II (Figure S4),
albeit activation was less robust, as aforementioned
(Figure 3 and Figure S1). Therefore, in this context,
TNT003 is more effective than anti-C5 at inhibiting HLA-
Ab induced early complement activation.
Discussion
The incidence of clinically evident AMR in solid organ
transplants (SOT) patients is 10–15% (60). The presence of
DSA prior to transplant, or development of de novo DSA,
negatively impact graft survival (61). DSA mediate injury to
the graft via three different mechanisms: (1) F(ab0)2-
dependent ligation of HLA molecules on the surface of
donor EC, triggering cellular activation and proliferation (16–
19); (2) Fc-dependent recruitment of activated leuko-
cytes (20,21) and (3) C1q binding of Fc in antibody-antigen
complexeswith subsequent complement activation (22,23).
Complement protein C4d deposition, as well as leukocytic
infiltrate are common pathological findings in AMR biop-
sies (3,6,7,45). Recent studies have demonstrated that
presence of complement-fixing DSA predisposes patients
to allograft rejection (62–64). As such, therapies targeted
to reduce both complement damage and leukocytic
infiltrate would be of value for treating episodes of AMR.
The data presented herein highlight the definitive role
of an anti-C1s monoclonal, TNT003, in blocking early
complement activation in vitro induced by HLA-Ab on the
Figure 6: TNT003 inhibits complement activation by AMR-associated DSA in a C3d bead-based assay. DSAþ sera from 10 cardiac
transplant patients with AMRþ biopsies were analyzed for C3d deposition. Three patients with DSA against HLA-I (A, n¼5) and 10 patients
with DSA against HLA-II (B, n¼15)were analyzed for C3d activation in the presence of control or TNT003 (25mg/mL). Each point represents
an allele recognized by DSA, and the dashed line at y¼1 is indicative of baseline C3d deposition. Fold change was calculated as in Figure 5.
(C) Percent inhibition of C3d by TNT003 was calculated for HLA-I and HLA-II-specific DSA. Percent inhibition was determined as follows:
[Fold C3d(control)Fold C3d(TNT003)]/[Fold C3d(control)]100. yAdditionally, this beadwas identified as a severe outlier (over three interquartile
ranges beyond the 75th percentile) and was removed from the data testing significance for the remaining beads.
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endothelial surface, the barrier between donor and
recipient. We demonstrate HLAI/II-Ab recognize and bind
HLA-I/II expressed on the surface of HAEC, and are
capable of activating human complement, resulting in
soluble anaphylatoxin production as well as complement
protein deposition on the surface of HAEC, B cells and
SAB. TNT003 inhibits HLAI/II-Ab-mediated complement
activation in a concentration-dependent manner, blocking
complement deposition at the cell surface and reducing
anaphylatoxin levels (Figures 1–4). Importantly, these
findings were verified using DSAþ sera from cardiac
transplant recipients undergoing AMR.
The complement-dependent cytotoxicity (CDC) assay, a
traditional cell-based assay, is used in histocompatibility
labs for delineating HLA-Ab specificity (65). However, the
assay does not discriminate complement activating HLA-
Ab fromotherHLA-Ab, as the use of rabbit complement and
human lymphocytes artificially enhances lysis (66), and
several groups have suggested cell lysis is not the major
mechanism of graft damage, nor the most accurate read-
out of HLA-Ab-mediated complement activation in vitro
(67,68). Studies utilizing human complement and/or EC
in vitro have endeavored to discern better markers of early
complement activation (69,70). Watanabe and Scornik (71)
demonstrated HLA-Ab-mediated human complement de-
position on the surface of lymphocytes by detection of
multiple complement proteins, but concluded that C3b
was the most specific determinant of activation. AlMahri
et al (46) established detection of HLA-Ab-mediated
complement induction by C3d staining on the surface
of endothelial progenitor cells (EPC) and lymphocytes
by flow cytometry. Similarly, another study showed that
sera containing HLAI/II-Ab can bind to IFN-g-treated
human umbilical vein endothelial cells (HUVEC) and deposit
C4d and polyC9 (47). In this work, we have established an
in vitro system using serum from sensitized individuals,
primary HAEC, and human complement in order to
ascertain HLA-specific inducible complement deposition
by flow cytometry. We show that sera with specificity
to HLA-I and/or HLA-II are capable of inducing human
complement activation on HAEC frommultiple donors with
disparate HLA alleles, as detected by C4d (Table S1 and
Figure 2). Furthermore, we show that increased levels of
HLA-I/II bound by HLAI/II-Ab on the surface of the cell lead
to a concomitant increase in complement activation,
consistent with other reports suggesting that complement
fixing capacity is a function of antibody titer in serum (72).
Notably, antibody concentration and characteristics (includ-
ing affinity, subclass, and glycosylation), as well as antigen
density are important indicators of the potential for
complement activation, as modulation of these factors
alter detectable levels of C4d complement activation (73).
For instance, we observed the levels of C4d mediated by
Figure 7: TNT003 blocks early complement activation more significantly than anti-C5 treatment. Pooled positive serum (PS) with
cPRA>80%wasmixed with three HLA-disparate EBV-immortalized B cells lines in the presence of control (IgG2a or IgG1, open circles) or
inhibitor (TNT003 or anti-C5, filled circles) (10mg/mL). IgG (A) and C4d (B) were measured by flow cytometry, whereas anaphylatoxins C3a
(C), C4a (D), and C5a (E) were measured by CBA technology. DD values were determined as follows: (valuesample/valueNS)¼Dsample;
DDsample¼Dsample(inhibitor)/averageDsample(control).
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purified high affinity HLA-I monoclonal antibodies were
greater than those elicited by the admixture of sub-
classes and high and low affinity HLA-I/II polyclonal
antibodies present in alloserum, further highlighting the
multifaceted dynamics of HLA-Ab-induced complement
activation.
The complement activation-dependent anaphylatoxins,
C3a and C5a, are mediators of leukocyte activation and
migration (74–78). Work determining the importance of
these anaphylatoxins in the field of transplant rejection has
elucidated effects of direct activation of lymphocytes and
endothelium, inducing proliferation and changes in vascular
permeability, respectively (79–84). Additionally, anaphyla-
toxin activation of antigen-presenting cells modulates the T
cell repertoire (85,86). In short, the presence of these
anaphylatoxins heavily influences alloimmunity. A treat-
ment, which minimizes the inflammatory milieu, reducing
cellular activation, and reshaping adaptive immune re-
sponses would be ideal for preventing transplant rejection.
Recently, TNT003 was demonstrated to inhibit anaphyla-
toxin (C4a, C3a and C5a) production in the context of cold
agglutinin disease (37). Our data also show TNT003 is
capable of decreasing anaphylatoxin production induced by
HLA-Ab, with significant blockade of C4a, further curtailing
the production of the potent immunomodulators C3a and
C5a. Due to the amplifying nature of the classical
complement pathway, inhibition at the beginning of the
cascade impacts early mediators more sharply than those
components further downstream. To this end, it would not
be surprising to find less severe histological findings
(endothelial swelling and leukocytic infiltrate) in biopsies
from patients undergoing treatment with a humanized
version of TNT003.
The SAB array, which detects HLA-Ab specificity in a high-
throughput manner, was a revolutionary technological
breakthrough, leading to personalized diagnostics and
patient care in the field of transplant medicine (87). Over
the past decade, these technologies have developed
further with the advent of assays that seek to stratify
DSA based on pathogenicity, such as the C1qScreen.
Multiple groups have reported C1qþDSAþ are predictive of
allograft damage and subsequent loss in SOT (62,64,88,89).
Our studies demonstrate the ability of a new Luminex-
based assay from Immucor to detect the functional capacity
of HLA-Ab to activate the classical complement pathway by
measuring C3d deposition (43,90). This assay provides a
physiological setting, as human complement is allowed to
interact with HLA-Ab Fc, and if steric hindrance allows (91),
activate intact C1 complex, leading to downstream
deposition of C3d. We show that sera from highly
sensitized individuals and DSA from cardiac transplant
patients with biopsy-proven AMR activated complement in
this assay. Notably, TNT003 strongly reduces this allele-
specific complement induction in vitro, further establishing
TNT003 as an effective inhibitor of early classical comple-
ment activation.
Current therapies are used in combination to treat the
multi-faceted pathophysiology of AMR, as there appears
to be no clear panacea (92,93). Traditional interventions,
such as plasmapheresis and intravenous immunoglobulin
(IVIG), are used to decrease antibody levels and inhibit
antibody function, respectively (94,95). Newer targeted
therapies have focused on modulating complement
proteins directly. C1-INH, an endogenous pleiotropic
protein involved in many processes, including inactivation
of C1s, is currently being tested in clinical trials
(NCT01147302 and NCT01134510) for its efficacy in
preventing AMR (96). Also available is the C5 mAb
eculizumab (NCT01327573 and NCT01399593), which
has received notice for equivocal ability to treat rejec-
tion (24,25,34–36). Blockade of C5, although potentially
useful in minimizing complement effects during rejection,
also prevents activation of the terminal complement
cascade, theoretically decreasing MAC-mediated patho-
gen clearance induced by all pathways of complement (1).
As SOT patients are already on immunosuppressive
regimens (97), reducing mechanisms of pathogen clear-
ance may not be ideal. TNT003 specifically targets the
classical complement pathway, potentially minimizing
damage to the allograft by blocking the formation of the
early products of HLA-Ab induced complement activation.
This may decrease endothelial activation and diminish
leukocyte recruitment to allograft tissue, thereby blocking
the feed-forward pathogenic loop of AMR. Moreover, as
TNT003 is specific for active C1s, and effective when
incubated with HLA-Ab prior to complement introduction,
as well as in the presence of complement, one could
deduce a humanized version of TNT003 would provide
therapeutic help whether administered prophylactically or
during active rejection.
As efficient as TNT003 is at blocking classical complement
activation, it does not inhibit the effects of HLA-Ab binding
to graft endothelium. Ligation of HLA-I/II on endothelium
activates multiple signaling networks and induces cyto-
skeletal remodeling and vascular permeability, which lead
to architectural changes in the vasculature of the graft. Also
of note, HLA-Ab still mediate Fc gamma receptor (FcgR)-
mediated effects, including enhanced rolling and tethering
of leukocytes to endothelium. Furthermore, as TNT003
blocks C1s activation, but not C1q binding (Figure S5), C1q
may bindHLA-Ab Fc, creating another theoretical handle for
C1qR-mediated leukocyte engagement. Therefore, a hu-
manized version of TNT003 used in combination with
modalities that minimize circulating DSA may be the most
effective method of reducing endothelial activation, leuko-
cyte recruitment, and graft failure.
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Figure S1: Surface expression of HLA-I/II and comple-
ment inhibitory receptors on cells. HAEC, either resting
or stimulated for 48 h with TNF-a/IFN-g, or resting EBV-
immortalized B cells weremeasured for expression of HLA-
I (A), HLA-II (B), CD46 (C), CD55 (D), and CD59 (E). Resting
or TNF-a/IFN-g stimulated HLA-A2þ HAEC or HLA-A2þ B
cells were incubated with 1mg/mL of HLA-A2 mAb in the
presence of NHS. IgG (F) and C4d (G) levels were
measured.
Figure S2: HLA-Ab induce C3d deposition in a concen-
tration-dependent manner. Clinically validated negative
(no HLA-Ab, NS) or positive (PRA >80%, PS) serum was
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analyzed using theC3d assay. Depositionwasmeasured on
HLA-I (A) or HLA-II (B) single antigen beads. Broadly
reactive HLA-I (C) or HLA-II (D) specific sera (see Tables S2
and S3, respectively) were diluted to measure the effect of
antibody titer on C3d deposition in the Luminex based C3d
assay.
Figure S3: TNT003 inhibits HLA-Ab-induced comple-
ment deposition on the surface of B cells. UCLA HLA
reference sera (see Tables S2 and S3) were incubated with
EBV-immortalized B cells in the presence of 25%NHS, and
C4d levels were measured by flow cytometry. Each dot
represents a reaction which contains a unique cell:sera
pairing. All reactions activated complement over that
induced by NS.
Figure S4: TNT003 blocks early complement activation
more significantly than anti-C5 treatment on HAEC.
Serawithmultiple specificitiesweremixedwith TNF-a/IFN-
g stimulated HAEC in the presence of control antibody
(IgG2a or IgG1, open circles) or inhibitor (TNT003 or anti-C5,
filled circles). IgG (A) and C4d (B) were measured by flow
cytometry, whereas anaphylatoxins C3a (C), C4a (D) and
C5a (E) were measured by CBA technology. DD values
were determined as follows: (valuesample/valueNS)¼
Dsample; D
D sample¼Dsample(inhibitor)/averageDsample(control).
Figure S5: TNT003 does not block C1q recognition of
HLA-Ab. TNT003 or control (‘‘C,’’ 100mg/mL) was titrated
into the C1qScreen assaywith a clinical positive serum (PS)
as a source of HLA-Ab. C1q positivity was recorded as
MFI> 1000, and measured on both HLA-I (A, n¼ 50) and
HLA-II (B, n¼ 13) SAB.
Table S1: Cell typing and sera for in vitro experiments.
Table S2: UCLA HLA reference sera: HLA-I Luminex
values.
Table S3: UCLA HLA reference sera: HLA-II Luminex
values.
Table S4: Cardiac transplant patient DSA and biopsy data.
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